Press Releases

AmerisourceBergen Corporation  today announced that it has signed a definitive agreement to acquire PharmaLex Holding GmbH, a leading provider of specialized services for the life sciences industry, from funds advised by AUCTUS Capital Partners AG for €1.28 billion in cash, subject to certain customary adjustments. The transaction will advance AmerisourceBergen’s role as partner of choice for biopharmaceutical manufacturers by enhancing AmerisourceBergen’s global portfol

Pherecydes Pharma , a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces the registration of its phagogram as an in vitro diagnostic test (“Phagogram 1.5”) in accordance with Directive 98/79/EC. The phagogram is an in vitro diagnostic test to verify the sensitivity of patients’ bacterial strains to Pherecydes Pharma’s phages. Hence only active phages are administered, incre

Spectrum Pharmaceuticals, Inc. a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that the U.S. Food and Drug Administration (FDA) has approved ROLVEDON™ (eflapegrastim-xnst) injection to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia. “RO

UroGen Pharma Ltd.  a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (“RSUs”) to 10 new employees in connection with their employment with UroGen. These new team members will support the ongoing commercial launch of Jelmyto® (mitomycin) for pyelocalyceal solution, UroGen’s first approved product, and the continued development

P360, a leading technology developer for pharmaceutical companies, today unveiled that its BirdzAI data and analytics platform has been enhanced with four powerful new pre-built modules for Master Data Management, Insights & Analytics, Sales Operations and Marketing Operations. With these enhancements, BirdzAI’s next-generation ecosystem supports pharmaceutical commercial operations with rapid, end-to-end data management capabilities, including the ingestion, storage, processing and

Zealand Pharma A/S, a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 7,802 divided into 7,802 new shares with a nominal value of DKK 1 each. The increase is a consequence of the exercise of warrants granted under several of Zealand Pharma's employee warrant programs. Employee warrant programs are part of Zealand Pharma’s incentive scheme, and e

InnoCare Pharma  announced today that the first patient was dosed in the phase II registrational trial (Registry number: CTR20221519) of tafasitamab in combination with lenalidomide for adult patients in China who have relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and are not eligible for autologous stem cell transplantation (ASCT). Dr. Jasmine Cui, Co-founder, Chairwoman and CEO of InnoCare, said, “DLBCL is the most common type of non-Hodgkin lymphoma1. We

Advanco SA today announced that it is partnering with Vantage Solutions to provide the first open, interoperable, and secure traceability solution for the Pharmaceutical Industry. advanco is widely recognized for its commitment to innovating track and trace software. Current serialization solutions in the Pharmaceutical Industry can be up to 20 years old. While pharmaceutical traceability solutions have matured considerably, systems remain proprietary and difficult to interface with

Stevanato Group S.p.A.  a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, and Gerresheimer AG, a leading global provider of healthcare & beauty and drug delivery systems for pharma, biotech and cosmetics, announce that they have jointly developed a high-end Ready-To-Use (RTU) solution platform with an initial focus on vials, based on Stevanato Group’s market-leading EZ-fill® techn

Good Therapeutics, a privately held company, today announced it has entered into a definitive merger agreement to be acquired by Roche . With this acquisition, Roche will gain rights to Good Therapeutics’ innovative, conditionally active, PD-1-regulated IL-2 program and an exclusive right to the platform technology for the development of PD-1-regulated IL-2 receptor agonist therapeutics. Under the terms of the merger agreement, Roche will make an upfront cash payment of $250 m